Colorectal cancer (CRC) is a common disease, with more than 13.500 new CRC patients per year in the Netherlands. Mortality rates are high, with more than 5000 CRC-related deaths in 2017. The aim of CRC translational research is to reduce mortality rates and to improve quality of life, through better diagnosis, prognosis, therapy prediction, and disease monitoring.

At present, the far majority of clinical decisions are based on standard clinico-pathological workflows. However, cancer is caused by molecular alterations that can be monitored on DNA and RNA level. It is the objective of Hartwig Medical Foundation to facilitate research to improve cancer care by generating and providing access to Whole Genome Sequencing (WGS) information of tumors.

The aim of the CRC focus group is to use data and expertise of Hartwig Medical Foundation to improve understanding and treatment of colorectal cancer, by defining collaborative research opportunities that can be carried out as joint efforts between research groups.

Remond Fijneman, the Netherlands Cancer Institute

Jan-Paul Medema, AMC

More information?